Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 8K |
| Gross Profit | -1M | -479K | -351K | -5K |
| Operating Income | -48M | -42M | -21M | -16M |
| EBITDA | -46M | -42M | -21M | -16M |
| Net Income | -44M | -42M | -21M | -15M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$3.02
-2.27% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cyteir Therapeutics, Inc. (CYT) is a Healthcare stock with a market cap of $108.71M. The stock last traded around $3.02. Baseline metrics include revenue growth of 0.0%, EPS growth of -5.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -5.9%, free cash flow -15.1% with operating margin 0.0% and ROIC -32.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CYT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CYT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CYT Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CYT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.0K
FY Net Income
-$15.0M
+27.8% YoY
Free Cash Flow
-$17.7M
+8.8% YoY
Revenue Growth
+0.0%
EPS Growth
-5.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 8K |
| Gross Profit | -1M | -479K | -351K | -5K |
| Operating Income | -48M | -42M | -21M | -16M |
| EBITDA | -46M | -42M | -21M | -16M |
| Net Income | -44M | -42M | -21M | -15M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Cash & Equivalents | 147M | 190M | 11M | 29M |
| Total Assets | 153M | 195M | 14M | 31M |
| Total Liabilities | 7M | 8M | 62M | 60M |
| Shareholder Equity | 146M | 187M | -48M | -28M |
| Total Debt | 889K | 0 | 0 | 0 |
| Net Debt | -146M | -190M | -11M | -29M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
18M
+5.3% YoY
Capital Expenditures
133K
+84.4% YoY
Free Cash Flow
18M
+8.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.4%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.